U.S. markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
138.09+0.55 (+0.40%)
At close: 04:00PM EST
139.51 +1.42 (+1.03%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close137.54
Bid138.50 x 1000
Ask140.00 x 1300
Day's Range137.57 - 138.81
52 Week Range94.75 - 144.78
Avg. Volume1,405,109
Market Cap310.582B
Beta (5Y Monthly)0.35
PE Ratio (TTM)40.61
EPS (TTM)3.40
Earnings DateN/A
Forward Dividend & Yield1.60 (1.16%)
Ex-Dividend DateAug 12, 2022
1y Target Est140.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
0% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novo Nordisk A/S
    Analyst Report: Novo Nordisk A/SWith almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more